Navigation Links
PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
Date:6/1/2009

KVISTGAARD, Denmark, June 1 /PRNewswire-FirstCall/ -- Detailed data from a randomized Phase 2 study with PROSTVAC(TM) were presented Saturday at the ASCO Annual Meeting in Orlando. The presentation was made by Philip Kantoff MD, Professor of Medicine, Harvard Medical School, and the Dana-Farber Cancer Institute who is also the principal investigator of the study.

The more detailed analysis supports the headline data that were reported in October 2008. In the Phase 2 prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer, patients in the PROSTVAC(TM) group had a significantly longer median overall survival by 8.5 months compared to the control group. The hazard ratio estimate for overall survival from the study is 0.56 (95% CI 0.37-0.85).

The statistical significance in the final data set is (p=0.006).

There were no major clinically meaningful imbalances in baseline characteristics in the PROSTVAC(TM) and control vector treated arms.

PROSTVAC(TM) immunotherapy was well tolerated, with some patients having injection site reactions (40-60%), and systemic symptoms of fatigue, fevers, and chills (10-30%) reported.

PROSTVAC(TM) is an 'off-the-shelf' viral vector-based immunotherapy, utilizing pox virus vectors that express PSA and three T cell costimulatory molecules are administered subcutaneously.

An abstract from Professor Kantoff's presentation is now available on ASCO's website:

   http://www.abstract.asco.org/AbstView_65_33254.html

    Slides from the presentation will be available within one week at:

   http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting

Philip Kantoff MD, Professor of Medicine, Harvard
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
2. Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
4. Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
5. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
6. Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies) Conference
7. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
8. Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS
9. Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
10. Pulmo BioTech Inc. Announces Paper to be Presented at Symposium
11. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 MabVax Therapeutics Holdings, Inc. (OTCQB: ... the Company,s lead antibody, HuMab 5B1, will be garnering ... during the upcoming World Molecular Imaging Congress (WMIC) being ... 2015. Researchers from the Department of Radiology at Memorial ... the use of MabVax,s lead antibody as a PET ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Middle East & Africa Biomedical Sensors Market - ... offering. The Middle East ... at $0.84 billion by 2018 at a CAGR of ... future will bring Biomedical sensors that are adaptable to ...
(Date:8/31/2015)... , Aug. 31, 2015  US-Australian drug discovery ... ) today confirmed its comprehensive scientific review has ... platforms in areas of unmet patient need. Novogen ... remaining preclinical projects prior to entering into Phase ... Acting Chief Executive Officer, Iain ...
(Date:8/31/2015)... Trimb Healthcare AB ("Trimb") today announced that it has ... a Dutch OTC company with operations in key European ... 16 million, with solid growth and leading brands in ... build a leading international OTC company, and this acquisition ... us a stronger North European OTC platform, from which ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Saudi Arabia Biomedical Sensors Market - ... offering. The Saudi Arabia Biomedical Sensors ... a CAGR of 3.64% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:8/26/2015)... 26, 2015 The report "Multi-Factor Authentication ... Factor), Application (Travel & Immigration, Government, Banking, Defense, Commercial ... to 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is ... at a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ...
(Date:8/24/2015)... The consulting company Frost & Sullivan ... DERMALOG and its customized solutions and products for ... the Year Award". DERMALOG is particularly successful with a large ... -Cross reference: Picture is available at AP Images ( ... Thursday evening, in South Africa,s economic ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3
... Association (ISWA) calls the attention of the delegates of ... waste sector to reduce substantial CO 2 -emissions. ... (December 2009, www.iswa.org ) ISWA confirms that significant ... better management of solid wastes (i.e., residential and commercial ...
... TORONTO, Dec. 7 IgeaCare Solutions Inc. is pleased to ... company previously operating as IgeaCare Systems Inc. The newly formed ... funding. , IgeaCare Solutions Inc. has appointed Mr. Michael Rochon ... the new company will focus on providing a superior servicing ...
... have found that a gene already implicated in the ... the risk of being overweight during childhood. The finding ... may present an avenue for developing drugs to counteract ... childhood and adolescence. Researchers from The Children,s Hospital ...
Cached Biology News:ISWA calls attention to important contribution of waste sector to reduce substantial CO2 emissions 2IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2Type 2 diabetes gene predisposes children to obesity 2
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
... ester can be used to ... The covalently bound acridinium NHS ... the presence of hydrogen peroxide. ... be used as a detection ...
A trigger solution for Flashlight labeled materials....
... shift assay (EMSA) is a powerful tool ... as gel shift or gel retardation, the ... when subjected to electrophoresis, free DNA will ... Pierce LightShift Chemiluminescent EMSA Kit is a ...
Biology Products: